Webinar Date/Time: Tue, Mar 26, 2024 11:00 AM EDT
Microdosing is one way in which a drug’s path to market can be accelerated by providing flexibility in dosage sizes. This webinar will explore how Lonza approaches a powder-in-capsule development campaign.
Register Free: https://www.pharmtech.com/pt_w/development-to-commercialization
Event Overview:
Microdosing can accelerate the journey of a drug product from early development through to commercialization. This webcast will look at the principles of microdosing and how Lonza goes about filling drug substance directly into a capsule using equipment such as the Xcelodose 600 or 600S, as well as the Harro Höfliger Modu-C Mid Speed Encapsulator. The two systems provide the flexibility to manufacture powder-in-capsule dosages in multiple strengths with rapid and accurate filling parameters.
Key Learning Objectives:
Who Should Attend
Speakers:
Mark Cappucci
Preformulation Team Lead
Lonza Small Molecules
Mark Cappucci serves as the Preformulation Team Lead at Lonza’s site in Tampa, Florida, USA. He has more than 26 years of experience in the pharmaceutical industry with expertise in areas including drug substance characterization, polymorph identification, and microdosing techniques using Lonza’s Xcelodose® system. Mark joined Lonza in 2004, after working for Amgen and Bausch & Lomb in positions of increasing authority. He received his BS in Chemistry from The Ohio State University.
Benito G. Graniela
MSAT Engineer II
Lonza Small Molecules
Benito Graniela is an MSAT Engineer II at Lonza's site in Tampa, Florida, USA. He has more than 6 years of experience in the pharmaceutical industry with expertise in areas including process development, scale-up, investigation root cause analysis, and lean manufacturing. Benito joined Lonza Tampa in 2021 and received his BS in Chemical Engineering from the University of Florida.
Register Free: https://www.pharmtech.com/pt_w/development-to-commercialization
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.